»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ <S68UN(Ke
jcL%_of
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 (]N- HN]v
szC<ht?z
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© Dbl+izF3
1.Antigen presenting cell£¨APC£© h1 pEC
2.Activation induced cell death£¨AICD£© ~kFL[Asnaf
3.Chemokine ;7E
c'nC4
4.Major histocompatibility complex£¨MHC£© Cd2A&RB
5.immunotolerance 9wbj}tN\z
Lv
UQ&NmY
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© g0ks[ }f-
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ Oe
~g[I;
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà y~n1S~5cI
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ WT63ve
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ Yhte&,D"
5.±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌصã 0T
Wd.+
LS]0 p#
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© #f<3[BLx
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ 7!Qu+R
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ ir|c<~_=
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ LyH1tF
%2y5a`b
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ {$g3R@f^~
,&.$r/x|?
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 Z+=M_{`{
$b(CN+#
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ k(he<-GF\
1.Antigenic determinant R.!.7dO
2.IgSF GZ^Qt*5 {
3.MBL;¾¶ X,{ 3_
4.chemokine &`oybm-p(
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ .cm2L,1h
6.TCR-CD3¸´ºÏÎï [ ou$*
7.FADD£¨Fas-associated protein with death domain£© w2db=9
8.AIDS q=}1
ud}1
9.Tumor rejection antigen F$bV}>-1k
10.AICD tuLNGU
`/^
_W
<
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ L7hRFf-o
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© /'VbV8%
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ A,BYi$
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ uFhaN\S
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì ]IE Z?+F,
AgZ?Ry
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ 'ZB^=T
`XpQR=IOMb
^Kg n:l
רҵ¿Î ÃâÒßѧ 2;u
i'B
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê fbU3-L?
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell P#7=h:.522
5. Fc¦Å receptor 6. Cytokine &a;?o~%*]i
¶þ¡¢ ÎÊ´ðÌâ mf)+ 5On
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØɱÉË°Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 f:-l}Zj
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ a]T&-#c,}
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁÜ°ÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ !nC
q8~#
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâЩÌصãµÄÉúÎïѧÒâÒ壿 tM^4K r~o,
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠr4fHD~#l{
p |1u,N
EG;E !0
H=Ilum06
5OppK(Oi*C
:Ys~Lt54
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 2Jio_Hk
JD~;.3$/k
4G?^#+|^
רҵ¿Î ÃâÒßѧ BUJ\[/
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê kB> ~Tb0
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen >
'hM"4f
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin CMaph
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test Z(T{K\)uN
9. Hybridoma technic 10.Mitogen P}Kgh7)3
11.Dentritic cell 12.Immunoproliferation [/UchU]DT
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ
/}(d'@8p
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨Äļ¸¸öÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ 0(D^NtB7
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ"|L"C+tE
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ lGl'A}]#$
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ |4Q*4s
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ La;G S
rtRbr_
XiE`_%NW
rP3HR5
Ki\.w~Qs
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ [|DKBJ
:oP LluW*
K^shT h8k
רҵ¿Î ÃâÒßѧ @h
%V:c
Ò»¡¢ Ãû´Ê½âÊÍ :"\,iH
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï 4Z( #;9f
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà &12KpEyf
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ am
u;grH
¶þ¡¢ ÎÊ´ðÌâ ~2w&+@dV%
1¡¢ TÁÜ°Íϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ *1b|j|5v
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁÜ°Íϸ°ûºÍЧӦÎïÖÊ¡£ `6D?te
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆ乲ͬÌص㼰ÓëÁÙ´²µÄ¹Øϵ¡£ <v:VA!]
4¡¢ ºÎνÁÜ°Íϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ ?Z7`TnG$uf
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØϵͳ£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ hmO2s/~
z8Q!~NN-K
&O&HczO
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 2bp@m;g$
OSgJj MQ
M"~jNe|
רҵ¿Î ÃâÒßѧ >l
Qo _p(;
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê +$dJA
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR 2/LSB8n|
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA z M9#1^X
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM eUyF
<j
¶þ¡¢ ÎÊ´ðÌâ Kg[OUBv
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌص㡣 `g)}jo`W
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ [GLH8R
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖƵÄÒìͬµã¡£ `fu_){
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆ书ÄÜ¡£ ZZw`8 E
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ 8+zW:0"[
37#&:[w>
P6:9o}K6
$~/2!T_
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ p@m0Oi,=
vl"w,@V7
t&r.Kf9Z\
רҵ¿Î ÃâÒßѧ _Cmmx`ln
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê +#}GmUwPG$
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule 2;}leZ@U
5. Autogous mixed lymphoyte reaction h [TwaR
¶þ¡¢ ÎÊ´ðÌâ wu41Mz7
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ @CMI$}!{V
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ a:kAo0@":j
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷ÓᣠpGbfdX
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹Øϵ£¿ LU1I
`E
IkrB}
6x+ujUBkK
E
C?}iP
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ oV|O`n
("$/sT
5E!C?dv(z
רҵ¿Î ÃâÒßѧ m4:c$5
uYJS=NGNA
b?H"/Mu.
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê JGs:RD'
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance ( }-*irSsj
5. Delayed type hypersensitivity SSK}'LQ
¶þ¡¢ ÎÊ´ðÌâ 6g(;2gY
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ 222 Y?3>@D
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ F%OP,>zl
3. ¼òÊöHLAÓëҽѧµÄ¹Øϵ¡£ S{c/3k~
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ8 Rx@_
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠAdX))xgl
4TtC~#D:
N*Y[[N(
i:lc]B
|v&)O)Jg
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ *?)MJ@
crmQn ^4\
0~|0D#klB
רҵ¿Î ÃâÒßѧ c&['T+X
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê -&+:7t
1. hypersensitivity 2. cluster of differentiation `3TR`,=
3. adhesion molecules 4. supper antigen 5. split tolerance Lg:1zC
¶þ¡¢ ÎÊ´ðÌâ \GFqRRn
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ 7e_4sxg'(3
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ y
saRH3M
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ ,@*5x'auK
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ E-A9lJWr
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ L]Tj]u)
\!ZA#7
1k[_DQ=^l1
Gb')a/
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ?QP>rm
רҵ¿Î ÃâÒßѧ [P2>KQ\
Ò»¡¢ Ãû´Ê½âÊÍ kQ\GVI11?
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å $tlBI:ay1
5. GVHR 8mX!mYO3c
¶þ¡¢ ÎÊ´ðÌâ rwWOhD)RU
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷Óᣠb9g2mW
L\T
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌصãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ FSu
C)Xg
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌص㡣 Z%~}*F}7X
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ c |0p'EQ
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ ^-%'ItVO
w1Bkz\95
Zma;An6
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ \Z.r Pq
FM]clC;X?
=svFw&q"
רҵ¿Î ÃâÒßѧ /&6{}n
Ò»¡¢Ãû´Ê½âÊÍ <Zva
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å r1~W(r.x
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ 4KH'S'eR
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ gmp@ TY=:L
11. »ìºÏÁÜ°Íϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ Xl=RaV^X"
Èý¡¢ ÎÊ´ðÌâ %
jDH{xSMb
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ bI.hG32
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ y,?=,x}o#
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà ~,,r\Y+
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ L IKuK#
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ SY9 5s
olv&K(-ccI
%C%3c4+Oh
I(UK9H{0$
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ E2|M#Y
"=2\kZ
#ChTel
רҵ¿Î ÃâÒßѧ 23|JgKuA
Ò»¡¢Ãû´Ê½âÊÍ =lv(
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó Ew4D';&;
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁÜ°Íϸ°ûµÄ±íÃæ±êÖ¾ 42e [OG-
Èý¡¢ ÎÊ´ðÌâ a<*+rGI
1. ¼òÊöTÁÜ°Íϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ &$ }6:
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ H/t0#
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ -qpvVLR,
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ Y"ta`+VJ
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ EFiVwH
Cw^iA
U
u/k'
ry=
C!_=L?QT^
`?T::&`
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ =Crl{Ax
Ò»¡¢Ãû´Ê½âÊÍ ;+DMv5A "
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï nls
$
wE
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó ,a
WI&ve6
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ -7oIphJ=\
¶þ¡¢ ÎÊ´ðÌâ E*R-Dno_F
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ +dCR$<e9r
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ Mg0a
i6KD
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ fx:vhEX
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ 9k4z__K e
e`B!)Sr
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ 3f>9tUWhTy
Ò»¡¢ Ãû´Ê½âÊÍ ao7M([ff
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡
w@mCQ$
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ 6wOj,}2Mn
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© w3iX "w
10¡¢ ÒõÐÔÑ¡Ôñ , iEGf-!k
¶þ¡¢ ÎÊ´ðÌâ sw$JY}Q8x
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 dtQ3iuV %
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ fyZtwl@6w#
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 e2xKo1?I
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ PTpfa*t
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. M"-53|#:w\
e*<pO@Uy
17:7w
G
=Xas"|
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ lBG5~<NT
Sw{rNzh%$
fX
LsLh+~D
רҵ¿Î ÃâÒßѧ )
[)1
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ pm}_\_
1. Cytokines 2. adhesion molecules 3. graft versus host reaction sld cI@Z
4. immunologic tolerance 5. Opsonization ASS<XNP
Èý¡¢ ÎÊ´ðÌâ ^MWp{E
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷ÓᣠS>[&]
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ [MAvU
?;
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ meD83,L~N
4. ÃâÒßϵͳɱÉË°Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ #E/|WT
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ "NV~lJS%
uY&t9L8
}dq)d.c
qz-lQ
;A?86o'?
oPxh+|0?
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ fo;^Jg.
Qj9'VI>&
c
S",Bw\
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ vf!lhV-UG+
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ V4<f4|IL
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê o3:h!(#G
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ KctbNMU]k
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û {UuSNZ[^
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö _.GHtu/I
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð DbN_(mC
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖƱ¸ÔÀí¡£ KhNE_.
Z
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ %hA0
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃ濹ԺͱíÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© 1{CVd m<9
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ rVb61$
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ !h+VbZ
DLEHsbP{$
?,UO$#Xm
`6Yk-5
O<+x=>_
b59NMGn
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ l\&Tw[O
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ wN$u^]
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ k mX:~KMb
z?g\w6
Ò»¡¢ Ãû´Ê½âÊÍ wGx*Xy1n<
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß a(K^/BT
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò 6F?U:N#<
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô fTV3lyk
¶þ¡¢ÎÊ´ðÌâ w*
IDL0#
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ uVLKR PY
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì 1y6{3AZm<
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì t|cTl/i
4
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ y(=$z/
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ <iznB8@
mI3
\
n